deborah fuller from the university of washington school of medicine. let's get to the stock of the hour. novavax may be the beneficiary, as the fda and cdc delay the shots from j&j. at least for a few days. over blood clotting fears. novavax could see a faster approval for its shots, with a 100 million does contract in the u.s. already set. ritika gupta is here with a look. britta: a mixed picture or mixed reaction from some of those vaccine makers off the back of this j&j news. if we look at this board, we are seeing astrazeneca down. that is not surprising. it has its own blood clot issues. to the upside, novavax, our stock of the hour, having its best day in over two months. they are developing a two does vaccine. it is up on the idea that their approval for the vaccine could be pushed forward. this news is outweighing some of more negative news on the side of its production, which seems to have hit a bit of a glitch. and did want to produce 150 million doses daily by the middle of this year. it is having to push that back to the third quarter. if t

with her expertise in microbiology from the university of washington, deborah fuller joins us.say good morning to all of you. i have to go back to our history. if we go back to the perfect child killer diphtheria, it was 1910. improvement in 1920. 30 years out to the advent of world war ii, where we finally figured out how to eliminate diphtheria. should we be using that timeline with this horrific pathogen? dr. fuller: we have an accelerated timeline compared to that. otherwise we will be fighting this virus for decades because, as we are seeing in india, this tinderbox of insufficient vaccines and returning restrictions, and you have the emergence of new variants. it is a cycle, it is a playbook we will see over and over again unless we can get on top of it quickly. tom: du, looking at bacteria and virology, just assume that within the joy and excitement of two vaccinations, we will have a regime of covid based vaccinations out two years and five years and forever? dr. fuller: we might. viruses are a bit different from bacteria in the rate they can undergo rapid mutation to r